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Abstract: In chronic obstructive pulmonary disease (COPD), there is large individual variability 
in the progression of the disease. Low amplitude of rest–activity rhythms has been associated 
with worse prognosis in a variety of diseases, but it has not been investigated in COPD. The first 
aim of this exploratory study was to compare disease severity and prognosis indicators between 
COPD patients with relatively high or low amplitude of their rest–activity cycle, as measured 
with actigraphy. As a second objective, 24-hour profiles of both activity levels and nighttime-
sleep quality were compared between the two subgroups to assess the relative contribution of 
day- and night-activity levels to high and low rest–activity rhythm amplitude in this popula-
tion. Rest–activity rhythms were measured with 8–14 days of wrist actigraphy in 14 patients 
(nine men), aged 58–79 years, suffering from moderate-to-severe COPD. Relative amplitude 
of 24-hour activity profiles ranged from 0.72 to 0.98. Participants were divided at the median 
into high-amplitude (mean ± standard deviation 0.9±0.04) and low-amplitude (0.79±0.05) 
subgroups. There was no significant difference between the two subgroups for pulmonary 
function or exercise capacity. However, the low-amplitude group had more severe symptoms 
of dyspnea and worse prognostic scores than the high-amplitude group (P<0.05). The 24-hour 
activity profiles revealed higher levels of activity in the high-amplitude group for the 12–3 pm 
interval (P<0.05). There was no significant difference between the two groups for subjective 
or actigraphic estimates of sleep quality, sleep duration, or proportion of daytime sleep. This 
exploratory study is a first step toward the identification of larger rest–activity rhythm ampli-
tude as a marker of better prognosis in COPD and as another potential target for exercise-based 
rehabilitation programs in this population.
Keywords: actigraphy, accelerometry, circadian rhythms, COPD, respiratory disorders, prog-
nosis, physical activity, sleep
Introduction
Studies on a variety of medical disorders, including cancer,1 Alzheimer’s disease,2,3 and 
hypertension,4 have found that larger amplitude in rest–activity rhythms is associated 
with lower disease severity and better prognosis. Rest–activity rhythms are usually 
measured with continuous actigraphic recordings, a technique that has the advantage 
of being noninvasive and providing results that are representative of patients’ usual 
behavior. In a recent review, Truong et al5 clearly demonstrated the impact of circadian 
rhythms in respiratory diseases. However, their review also highlighted the scarcity 
of literature on this topic in chronic obstructive pulmonary disease (COPD). To our 
knowledge, the association between amplitude of the rest–activity cycle and disease 
severity and prognosis has not been investigated in COPD patients.
Correspondence: Marie Dumont
Chronobiology Laboratory (J-5185), 
Sacré-Coeur Hospital of Montreal, 
5400 Gouin Boulevard West, 
Montreal, QC H4J 1C5, Canada
Tel +1 514 338 2222 ext 2246
Fax +1 514 338 2531
Email marie.dumont@umontreal.ca
Journal name: ChronoPhysiology and Therapy
Article Designation: ORIGINAL RESEARCH
Year: 2016
Volume: 6
Running head verso: Chan-Thim et al
































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





COPD is a respiratory disorder that develops over time 
and is progressive by nature. It is a leading cause of mor-
bidity and mortality worldwide.6 The most common cause 
of COPD is the inhalation of noxious particles, such as 
cigarette smoke. Airflow is obstructed by such factors as 
inflammation in the bronchioles, mucus hypersecretion, and 
destruction of the lung parenchyma, leading to the collapse of 
the alveoli and gas trapping in the lungs.7 Destruction to the 
lungs cannot be reversed with current therapy; therefore, the 
management of COPD aims to control symptoms and slow 
down the progression of the disease.8 The severity of COPD 
is traditionally measured by the degree of airflow limitation 
and the presence of respiratory symptoms (dyspnea, cough, 
phlegm, or wheezing), which have both been associated with 
increased mortality.9
The progression of COPD is typically manifested by a 
decline of about 30–60 mL per year in forced expiratory 
volume in 1 second (FEV
1
).10–12 However, the rate of decline 
in lung function in COPD is not uniform, and the progression 
of the disease is quite variable among patients. For instance, 
individuals who experience frequent exacerbations (more 
than two per year), a worsening of their respiratory symptoms 
usually caused by a respiratory infection, have demonstrated 
a faster rate of decline.13 Life-threatening exacerbations have 
been associated with a phenotype that includes low body 
mass index (BMI), low exercise capacity, high dyspnea score, 
and severe airflow obstruction. In this respect, a composite 
index combining these four indicators, the BODE (BMI, 
airflow obstruction, dyspnea, exercise capacity) index, has 
been developed and used as a good predictor of mortality 
risk in COPD patients.14 BODE index prognosis value is 
further improved when supplemented with a comorbidity 
index, the Comorbidity Test (COTE) index, in which other 
conditions commonly associated with COPD (eg, cardiovas-
cular disease, depression, sleep apnea) are integrated into a 
weighted score.15,16
In a study published in 2014,17 we reported the impact of 
time of day on exercise capacity in 14 COPD patients, studied 
using a counterbalanced repeated-measure design. Patients 
were evaluated three times over a period of 8–14 days, during 
which they filled out sleep and mood diaries and underwent 
continuous actigraphic recordings. Mood data were published 
in 2016.18 For the present paper, we took advantage of acti-
graphic data to explore the possible difference in disease-
severity and prognosis indices between COPD patients with 
relatively high or low amplitude in rest–activity rhythm, with 
the expectation of finding lower severity and better prognosis 
in the subgroup of patients with larger amplitude. We adopted 
the approach chosen by Bromundt et al,19 who used median 
amplitude to split a sample of schizophrenia patients into 
subgroups of lower and higher amplitude of rest–activity 
rhythms to compare their levels of cognitive functioning. 
As a second objective, actigraphic data were also used to 
compare profiles of 24-hour activity levels and indicators of 
nighttime-sleep quality between the two subgroups to evalu-
ate their respective contribution to high and low amplitude 
of rest–activity rhythms in this population.
Materials and methods
Participants
Fourteen patients with diagnosed COPD were recruited at the 
Hôpital du Sacré-Coeur de Montréal over an 8-month period. 
Recruitment was based on information reported in medical 
records. All patients were clinically stable and presented with 
moderate (n=12) or severe (n=2) airflow obstruction accord-
ing to GOLD (Global Initiative for Chronic Obstructive Lung 
Disease) classification criteria:20 postbronchodilation FEV
1
 
less than 80% of the predicted normal value, and FEV
1
 to 
forced vital capacity (FVC) ratio less than 70%. All patients 
were aged 40 years or older, had a smoking history of at least 
10 pack-years (20 cigarettes per pack), and had prior exercise-
testing experience. Exclusion criteria were: 1) a respiratory 
exacerbation in the past 4 weeks, as reported by the patient 
at recruitment and at the beginning of the study (change in 
dyspnea or volume/color of sputum, need for antibiotic or 
systemic corticosteroid treatment, or hospitalization); 2) 
active condition other than COPD that could influence exer-
cise tolerance; 3) need for oxygen therapy; and 4) prescribed 
theophylline. The local ethics research committee of Hôpital 
du Sacré-Coeur de Montréal approved the research project, 
and all participants signed an informed consent prior to taking 
part in the study. Detailed description of clinical character-
istics and inclusion/exclusion criteria for the participants is 
provided in a previous publication.17
Study design and procedure
Data presented in this paper were collected in a study evaluat-
ing the impact of time of day on acute response to incremental 
exercise in COPD patients, and detailed methodology has 
been published in a previous publication.17 Briefly, the study 
required four hospital visits, 8–14 days of actigraphy, and a 
sleep–wake diary. At visit 1, BMI and baseline pulmonary 
function were measured, and depression and anxiety symp-
toms were assessed using the Center for Epidemiological 
Studies – depression (CES-D) questionnaire21 and the Beck 
Anxiety Inventory (BAI),22 respectively. Visits 2–4 were 
scheduled at least 36 hours apart, included pulmonary func-
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Rest–activity cycle in COPD
time of day (8 am, 12 pm, or 4 pm). Patients were asked to 
withhold respiratory medication for at least 6 hours before 
each visit. Ambulatory activity recording and sleep diaries 
were initiated at visit 1 and ended at visit 4. Comorbidities 
and dyspnea level were obtained from medical records.
Evaluation of disease severity
Three measures were used to assess COPD severity: a subjec-
tive measure of dyspnea, an objective measure of pulmonary 
function, and a measure of peak exercise capacity. Participant 
dyspnea levels were obtained from medical records, as ascer-
tained during the respirology appointment closest to the study 
(range 0–15 months, median 1 month). These were measured 
with the modified Medical Research Council (mMRC) dys-
pnea scale.23,24 The mMRC dyspnea scale is a 5-point scale 
that corresponds to statements related to physical activity 
and level of breathlessness: grade 0, breathless with strenu-
ous exercise; grade 1, short of breath when hurrying on level 
ground or walking up a slight hill; grade 2, walks more slowly 
than people of the same age on level ground, and experiences 
breathlessness or the need to stop to catch breath when walk-
ing on level ground at their own pace; grade 3, stops to catch 
breath after walking about 100 m or after a few minutes on 
level ground; and grade 4, too breathless to leave the house, 
or breathless when dressing and undressing.23
Pulmonary function was assessed at visit 1 with spi-
rometry using cardiometabolic equipment (Oxycon Pro; 
BD, Franklin Lakes, NJ, USA). All patients were evaluated 
between 10:30 am and 3 pm. Spirometry was performed with 
the patient seated, as per recommended procedures.25 At least 
two to three normal tidal breaths were taken, followed by a 
maneuver where a full inspiration of air was immediately 
followed by a full and forceful expiration, until maximal 
expiration was reached. The total volume of air expired 
during the maneuver was recorded as FVC, and the volume 
expired within the first second of expiration was recorded 
as the FEV
1
. The maneuver was repeated to obtain three 





:FVC ratio was recorded. In addition to absolute 
values, measures were normalized to account for differences 
in sex, age, and height for a Caucasian population, using the 
predicted normal values from the European Community for 
Coal and Steel/European Respiratory Society.26 The resulting 
value of FEV
1
% predicted was used to classify the severity 
of airflow obstruction.
Exercise capacity was evaluated at visits 2–4 using an 
electromagnetically braked cycle ergometer (Ergoselect 
200P; Ergoline GmbH, Bitz, Germany), with participants 
connected to cardiometabolic equipment (Oxycon Pro). 
Participants performed symptom-limited incremental cycling 
exercise tests according to a standard protocol.27 Testing 
began with 5 minutes of rest and 3 minutes of unloaded 
pedaling, and then the workload was increased in a stepwise 
manner by 5–10 W every minute up to the individual’s maxi-
mal capacity. Standardized instructions were given prior to 
each test, and verbal encouragement given during the test 
was standardized at every 30 seconds. Maximal exercise 
capacity was recorded as the highest workload achieved and 
maintained for at least 30 seconds at a pedaling rate of 50 
revolutions per minute. Peak oxygen consumption (VO
2max
) 
was calculated for each test as average VO
2
 obtained over the 
last 30 seconds of the test. The mean of the results obtained 
at the three visits was then expressed as a percentage of the 
predicted normal value according to sex, age, and weight.28
Evaluation of disease prognosis
Two measures were used to evaluate disease prognosis: the 
BODE index and the COTE index. The BODE and COTE 
scores were also summed to form a composite score, which 
has been demonstrated to be a better predictor of mortality 
than individual scores alone.15,16
The BODE index is a composite measure of body com-
position, airflow obstruction, dyspnea rating, and exercise 
capacity. The following elements account for the traditional 
BODE index: BMI as the measure of body composition, 
FEV
1
 (% predicted) as the measure of airflow obstruction, 
mMRC score as the dyspnea rating, and distance walked on 
a 6-minute walking test as exercise capacity.14 In the present 
study, a modified BODE index (mBODE%) was calculated, 
where percent VO
2max
 was used as a measure of exercise 
capacity in replacement of 6-minute walking distance. This 
approach has been proposed and previously validated by 
Cardoso et al.29 Scores on the mBODE% index range from 
0 to 10, indicating low to high risk of death, respectively.14,30
The COTE index was calculated based on information 
reported verbally by the participant during the hospital vis-
its and completed by a review of the participant’s medical 
records. The COTE index categorizes comorbidities into 
12 domains found to be associated with an increased risk of 
mortality in COPD patients:15 oncologic (lung, pancreatic, 
esophageal, and breast cancer), pulmonary (pulmonary fibro-
sis), cardiac (atrial fibrillation/flutter, congestive heart failure, 
coronary artery disease), gastrointestinal (gastric/duodenal 
ulcers, liver cirrhosis), endocrine (diabetes with neuropathy), 
and psychiatric (anxiety). Each of these comorbidities is 
associated with a specific score. The final COTE score can 
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Evaluation of amplitude of rest–activity 
cycle
Activity recordings were conducted with an actigraph 
equipped with an event marker (Actiwatch 2; Philips, 
Amsterdam, Netherlands). The monitor was worn on the 
nondominant wrist, 24 hours per day, for a minimum period 
of 8 consecutive days (range 8–14 days). Participants were 
instructed to press the event marker at bedtime, when ready 
to sleep, and upon waking in the morning. Periods of nonwear 
of the actigraph monitor (eg, for bathing) were identified 
using the sleep–wake diaries and then excluded from the data. 
Further missing data were visually identified and removed 
based on the following published criteria: when more than 
50% of the activity was missing per hour, the entire hour was 
excluded from the analyses,31 and when 3 or more hours were 
missing in the 24-hour period, the entire day was excluded.19 
The mean of 1-minute data was calculated for each valid 
hour of recording, and then the 1-hour means were averaged 
for each clock hour across the days of recording to obtain a 
24-hour profile.
To estimate amplitude of the rest–activity rhythm, 
we calculated relative amplitude (RA), a nonparametric 
indicator that makes no assumptions about the shape of 
the rhythm.32 The 10 consecutive most active hours of the 
day and the 5 consecutive least active hours of the night 
were identified from the 24-hour profile. RA was then 
calculated as the ratio of activity during the 10 most active 
hours minus activity during the 5 least active hours over 
the sum of activity during the 10 most active and 5 least 
active hours.
Comparison of 24-hour activity levels
Using the approach of Bromundt et al,19 activity counts were 
log-transformed and collapsed into 3-hour bins. Resulting 
profiles were then compared between patients with higher and 
lower RA to determine the presence of differences between 
the two groups of patients.
Evaluation of nighttime-sleep quality
One-minute actigraphic data were also used to estimate 
some indicators of nighttime-sleep quality. Data were scored 
with dedicated software (Actiware version 5.7; Philips) 
using a medium wake threshold (40 activity counts). For 
each data set, the actogram was visually inspected and 
compared with the participant-reported times via the event 
marker and sleep diaries. For each night of recording, bed-
time and wake time were set using information from the 
sleep–wake diaries, data from the event marker, and visual 
inspection of the actogram. The interval between bedtime 
and wake time defined the duration of time in bed. Other 
variables were computed by the software, and included 1) 
sleep latency (number of minutes between bedtime and sleep 
onset, with sleep onset defined as the beginning of the first 
10 consecutive minutes of sleep), 2) total sleep time (total 
number of minutes scored sleep), and 3) sleep efficiency 
(total sleep time divided by duration of the sleep episode 
×100). Sleep efficiency was the main variable used as an 
objective estimate of sleep quality.
Sleep–wake diaries
On each day of ambulatory recording, participants filled a 
sleep diary to report bedtime and wake time, as well as pres-
ence and duration of daytime naps. These reports were used 
to calculate the subjective estimate of total duration of sleep 
per 24 hours and the percentages of daytime sleep in the total 
24-hour sleep. Subjective sleep quality was reported using 
a Likert scale from very bad (1) to very good (5) quality.
Statistical analyses
The 14 participants were split into two groups of seven 
patients having higher or lower rest–activity rhythm ampli-
tude, using median RA as a threshold.19 Data normally 
distributed were compared between the two groups using 
Student’s t-test. Analysis of covariance (ANCOVA) was used 
to control for age in comparisons yielding significant group 
differences. Comparisons of 24-hour activity profiles were 
conducted using a group-by-time (2×8) analysis of variance 
(ANOVA) adjusted with Huynh–Felt correction for repeated 
measures (original degrees of freedom are reported). Results 
are presented as mean ± standard deviation, and the level of 
significance was set at P<0.05. Analyses were performed 
using SPSS version 23.
Results
Participants
Participants comprised nine men and five women aged 
58–79 years (71±7 years). Clinical characteristics of the 14 
participants are presented in Table 1. All participants had 
moderate-to-severe COPD, and most had a moderate mMRC 
dyspnea index score (index of 2). The average time since 
diagnosis was 5±3 years, and eleven (79%) participants were 
retired. All participants had previously been smokers, and two 
(14%) remained active smokers. Twelve participants (86%) 
were using short-acting anticholinergic medication at the time 
of the study. Nine participants (64%) used combination prod-
ucts of long-acting β
2
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Rest–activity cycle in COPD
Amplitude of rest–activity rhythm and 
COPD severity and prognosis
RA ranged from 0.72 to 0.98 (0.84±0.07). The RA median-
split cutoff in our sample was 0.855. Mean RA was 0.79 
(±0.05) in the low-amplitude group and 0.9 (±0.04) in 
the high-amplitude one. Comparisons of clinical variables 
between the two groups are presented in Table 2. Respiratory 
function (FEV
1
% predicted) and exercise capacity (VO
2max
% 
predicted) did not differ significantly between the two groups, 
but the low-amplitude group had more severe symptoms of 
dyspnea (mMRC score) and worse prognosis according to 
COTE and BODE + COTE scores compared to the high-
amplitude group. There was no significant difference between 
the two groups for BMI.
Both age and psychological distress can influence clini-
cal variables. Participants of the low-amplitude group were 
significantly older (75±5.2 years) than participants of the 
high-amplitude group (67.9±6.6 years) (P=0.04). When 
controlled for age using an ANCOVA, group differences 
remained significant for mMRC dyspnea score (P=0.02) and 
BODE + COTE score (P=0.049), but not for COTE score 
(P=0.06). Psychological screening questionnaires yielded 
similar results between the two groups for depression (CES-D 
scores 12.9±10.3 vs 11.3±9.9 in low- and high-amplitude 
groups, respectively; P=0.78), and were not significantly dif-
ferent for anxiety (BAI scores 10.4±6.8 vs 8±7.2 in low- and 
high-amplitude groups, respectively; P=0.18).
Amplitude of rest–activity rhythm and 
24-hour activity levels
ANOVA showed no significant group effect (F
1,12
=0.86, 
P=0.37), but the group-by-time interaction was significant 
(F
7,84
=2.53, P=0.02). Simple-effect analyses revealed higher 
levels of activity in the high-amplitude group in the inter-
val 12–3 pm (P=0.03), with a similar trend for the interval 
9 am–12 pm (P=0.08). Results are illustrated in Figure 1.
Amplitude of rest–activity rhythm and 
sleep timing and quality
For each participant, reported sleep variables represent 
values averaged over 6–12 days of recording (mean 9.1±2.6 
days). One participant from the low-amplitude group did 
not complete the sleep diary on all days; therefore, subjec-
tive sleep quality and diurnal sleep to total 24-hour sleep 
are available for only 13 subjects. On average, participants 
were in bed from 10:49 pm (±37 minutes) to 6:51 am 
(±49 minutes), with a sleep-onset latency of 22.3 (±17.8) 
minutes and a sleep efficiency of 85.6% (±6.8%). Partici-
Table 1 Clinical characteristics of the 14 participants
Variable Number/mean ± SD Range
COPD stage (II/III/IV) 12/1/1 II–IV
mMRC dyspnea score (2/3/4) 8/3/3 2–4
FEV1% predicted 58±13 23–76
FEV1/FVC (%) 53±11 38–75
VO2max% predicted 72±14 46–96
BMI (kg/m2) 27±4 22–35
mBODE% index 3±2 1–7
COTE index 1±1 0–4
BODE + COTE 4±3 1–8
Abbreviations: SD, standard deviation; COPD, chronic obstructive pulmonary 
disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; 
mMRC, modified Medical Research Council; VO2max, maximal oxygen consumption; 
mBODE, modified BODE (BMI, airflow obstruction, dyspnea, exercise capacity; 
index using VO2max% predicted); COTE, comorbidity test (COPD-specific); BMI, 
body mass index.
Table 2 Comparison of clinical variables (mean ± SD) between 
participants with high or low relative amplitude of the rest–
activity cycle







mMRC dyspnea score 3.14±0.9 2.14±0.38 0.026
FEV1% predicted 58±7.77 57.71±17.29 0.97
VO2max% predicted 67.4±12.37 76.37±14.86 0.24
BMI 28.8±4.3 25.5±3.6 0.15
mBODE% index 3.86±1.57 2.43±2.15 0.18
COTE index 1.71±1.5 0.29±0.49 0.046
BODE + COTE 5.57±1.72 2.71±2.43 0.026
Abbreviations: SD, standard deviation; mMRC, modified Medical Research 
Council; FEV1, forced expiratory volume in 1 second; VO2max, maximal oxygen 
consumption; BMI, body mass index; mBODE, modified BODE (BMI, airflow 
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Figure 1 Activity counts (mean ± standard deviation of log-transformed data).
Notes: Counts averaged for the next 3 hours (eg, data reported at 3 h represent 
mean activity counts measured between 3 and 6 am) for patients divided at the 
median into low and high relative amplitude groups (n=7 in each group). Asterisk 
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pants reported fair-to-good subjective sleep quality (range 
3.17–4.31). Ten  participants (77%) reported daytime naps, 
with a mean duration of 49±21 minutes. Table 3 presents 
the comparisons of sleep variables between low- and high-
amplitude groups. There was no significant group difference 
for either actigraphic measures or subjective estimates of 
sleep timing and quality.
Discussion
The main objective of this paper was to compare disease 
severity and prognosis indices in COPD patients with lower 
or higher amplitude of rest–activity rhythm. Significant dif-
ferences between subgroups of low and high RA were found 
for dyspnea severity and for the combined prognosis score 
BODE + COTE, but not for respiratory function or exercise 
capacity. Differences were in the expected direction, with 
patients with lower RA for rest–activity rhythms displaying 
greater symptom severity and worse prognosis.
There is currently no accepted threshold to determine a 
“normal” level of RA for rest–activity rhythms. However, 
using a median split to divide our group of patients into 
high- and low-amplitude subgroups, we obtained a threshold 
of 0.855, similar to the threshold of 0.85, also found with a 
median split, by Bromundt et al19 in their group of 14 middle-
aged schizophrenia patients. Moreover, the mean RA in our 
high-amplitude group (0.9) was similar to theirs (0.93) and 
was also similar to the median amplitude (0.91) they observed 
in an independent group of 23 healthy individuals slightly 
younger (64±5.4 years) than our participants. In another 
study, a mean RA of 0.86 (±0.02) was reported in ten older 
(73±1.5 years) healthy men.32 RA higher than 0.85 thus 
seems to be representative of healthier older individuals, but 
larger studies will be needed to determine a valid “normal” 
threshold in different age-groups.
Many factors may contribute to decreased amplitude of 
rest–activity rhythms, an important one being older age.33,34 
We found that participants in the low-RA group were sig-
nificantly older than those in the high-RA group. However, 
there was no significant difference in age between patients 
with moderate (mMRC score 2, n=8, age 70.3±7.3 years) or 
severe (mMRC score 3–4, n=6, age 73±6.4 years) dyspnea 
symptoms (P=0.48). Furthermore, group differences in both 
dyspnea score and BODE + COTE prognosis index remained 
significant when the effect of age was taken into account in 
ANCOVA. Statistical control is very limited in this small 
number of subjects, but our results suggest that the age dif-
ference was not the main factor that explains the differences 
in dyspnea symptoms and prognosis between the two RA 
subgroups. Among other factors previously associated with 
lower amplitude of rest–activity rhythms are high BMI35 
and symptoms of depression and anxiety.36–38 In the present 
study, there was no significant difference between the high-
RA and low-RA subgroups for BMI nor for psychological 
distress evaluated with validated questionnaires. Because of 
the limited statistical power in this study, a contribution of 
these variables cannot be completely excluded, but they do 
not appear to be major factors explaining increased dyspnea 
symptoms and worse prognosis in the low-amplitude group.
Low amplitude of rest–activity rhythms may reflect dis-
turbed nocturnal sleep and/or decreased daytime activity; 
both have been found to be associated with decreased ampli-
tude in healthy aging.33 Presumably in COPD, symptoms of 
breathlessness associated with severe dyspnea could result in 
more nighttime awakenings39 and in turn reduce rest–activity 
amplitude by increasing nighttime activity. Other medical 
conditions associated with worse prognosis, as assessed with 
the COTE index, may also decrease nighttime-sleep quality. 
However, sleep quality and total sleep time were not signifi-
cantly different between our two subgroups of high and low 
RA. In Bromundt et al,19 with the same number of subjects, it 
was clearly greater nighttime activity that characterized their 
low-RA group (P<0.001). In our group of COPD patients, 
ANOVA rather identified lower daytime-activity levels as 
the main factor contributing to low amplitude, especially at 
midday (Figure 1). As our two subgroups were very similar 
for total 24-hour sleep time and proportion of daytime sleep 
(Table 3), increased napping in patients included in the low-RA 
group does not seem likely. Therefore, the amplitude differ-
ence between the two subgroups appears to have been due to 
increased physical activity at midday in the high-RA subgroup.
Table 3 Comparison of sleep variables (mean ± standard 
deviation) between participants with high or low relative 
amplitude of the rest–activity cycle







Bedtime (24-hour clock) 22:51±00:25 22:48±00:49 0.86
Wake time (24-hour clock) 07:08±00:54 06:34±00:41 0.2
Time in bed (hours) 8.3±0.8 7.7±0.9 0.24
Sleep latency (minutes) 24.5±21.6 20.0±14.6 0.65
Total sleep time (minutes) 382±64 379±63 0.95
Sleep efficiency (%) 82.8±6.5 88.4±6.2 0.13
Subjective sleep qualitya 3.7±0.4 3.9±0.3 0.5
Total 24-hour sleep (minutes)a 535±65 511±71 0.53
Diurnal/24-hour sleep (%)a 6.76±4.22 6.85±5.55 0.98
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Rest–activity cycle in COPD
While a direction of causality cannot be established in this 
study, it can be hypothesized that patients with more severe 
symptoms of dyspnea and more comorbidities were more 
sedentary, leading to reduced levels of daytime physical activ-
ity and decreased amplitude of rest–activity rhythms. Indeed, 
reduced physical activity levels in COPD have been associ-
ated with increased dyspnea ratings on the mMRC scale,40 
comorbid chronic illnesses, such as heart disease and type 
2 diabetes,41,42 and a worse score on the BODE index.40,43 In 
our COPD patients, respiratory function (FEV
1
% predicted) 
and exercise capacity (VO
2max
% predicted) were not statisti-
cally different between low-RA and high-RA subgroups, 
suggesting that it was not the severity of airflow obstruction 
that was restrictive for daytime activity. Symptoms of dys-
pnea were more severe in the low-RA subgroup. However, 
symptoms of dyspnea are usually worse in the morning,44,45 
and we observed differences in daytime activity, mostly in 
the early afternoon. Therefore, more than just symptoms of 
dyspnea may have been influencing the amplitude of the 
rest–activity rhythm in our COPD patients.
Increased comorbidity in our low-RA group is consistent 
with reduced amplitude of the circadian rest–activity cycle 
reported in other disease conditions, such as hypertension,4 
cancer,1 and mood disorders,46 all conditions taken into 
account by the COTE index. In their study of schizophrenia 
patients, Bromundt et al19 found that low amplitude could 
be associated with disturbances of circadian rhythms, as 
shown by a delayed onset of melatonin secretion in relation 
to sleep time, and they proposed that circadian asynchrony 
may explain the strong association they found between low 
amplitude and low scores on many tests of cognitive func-
tions. There were no measures of endogenous circadian 
markers in the present study, but sleep timing and duration 
were in the normal range and similar in the two amplitude 
subgroups. Therefore, there was no indication of an abnormal 
circadian phase in the low-RA subgroup. The only indication 
of a possible circadian dysfunction was the lower RA. Low 
amplitude of rest–activity rhythms has been found to be an 
independent prognostic factor for cancer patients’ survival,38 
suggesting the possibility of a two-way relationship between 
circadian amplitude and severity of clinical symptoms.
This study was an exploratory investigation of clinical 
differences between COPD patients with higher or lower 
amplitude of the rest–activity rhythm. This exploration was 
conducted on patients recruited for a broader study with differ-
ent aims.17 As such, the study has some limitations, including 
a relatively small sample size and the absence of a control 
group of age-matched healthy subjects. A larger sample would 
allow for the inclusion of a larger spread in disease severity, 
symptom ratings on the dyspnea scale, exercise capacity, and 
comorbidities, and would also allow for a more efficient control 
of possible mediators, such as age, BMI, and psychological 
distress. An age-matched control group would help to inter-
pret differences in RA and set boundaries for a normal range. 
Another limitation is that the dyspnea score was obtained at 
participants’ medical visit closest to the study, which in two 
cases exceeded 6 months from the study visit. However, the 
mMRC scale is relatively insensitive to small changes in clini-
cal status and to therapeutic intervention.47,48 Inclusion criteria 
required that only clinically stable patients were enrolled in the 
study; therefore, the range in assessment time for the mMRC 
scale should not have had a significant effect on this measure.
Conclusion
This study is a first step toward the identification of larger 
rest–activity rhythm amplitude as a marker of better prog-
nosis in COPD and as a potential target for exercise-based 
rehabilitation programs in this population.49 Direction of 
causality cannot be determined in this study, but regular 
practice of physical activity may contribute to endogenous 
circadian amplitude and may have a synchronizing effect on 
circadian rhythms.32,50,51 Beneficial effects of physical activ-
ity may thus extend beyond increasing physical fitness, and 
positively impact on circadian physiology to improve quality 
of life and decrease mortality in COPD patients.
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